This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Celgene Down on Discontinued Crohn's Disease Drug Study
by Zacks Equity Research
Shares of Celgene Corporation (CELG) declined after the company announced that a phase III trial, REVOLVE, (CD-002) on pipeline candidate GED-0301 in Crohn's disease and the extension trial, SUSTAIN (CD-004) will be discontinued.
What's in the Cards for Amgen (AMGN) this Earnings Season?
by Zacks Equity Research
While Amgen's (AMGN) growth drugs like Prolia & Xgeva might continue to do well, biosimilar competition and slowdown in sales of mature products can put pressure on sales growth.
Is a Beat in the Cards for Vertex (VRTX) in Q3 Earnings?
by Zacks Equity Research
Vertex's (VRTX) Kalydeco is expected to generate increased revenues following its label expansion in the third quarter of 2017.
The Zacks Analyst Blog Highlights: IBM, Celgene, Procter & Gamble, Valero and Sprint
by Zacks Equity Research
The Zacks Analyst Blog Highlights: IBM, Celgene, Procter & Gamble, Valero and Sprint
Zacks Industry Outlook Highlights: Novo, Vertex Pharmaceuticals, Celgene and Ligand Pharmaceuticals
by Zacks Equity Research
Zacks Industry Outlook Highlights: Novo, Vertex Pharmaceuticals, Celgene and Ligand Pharmaceuticals
Immune Design's Sarcoma Candidate to Enter Phase III in 2018
by Zacks Equity Research
Immune Design (IMDZ) plans to initiate a pivotal phase III study to support a Biologics License Application (BLA) for CMB305.
The Zacks Analyst Blog Highlights: Bayer Aktiengesellschaft, Monsanto, Adaptimmune Therapeutics and Celgene
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Bayer Aktiengesellschaft, Monsanto, Adaptimmune Therapeutics and Celgene
Glaxo's Shingles Vaccine Shingrix Gets Approval in Canada
by Zacks Equity Research
GlaxoSmithKline plc (GSK) announced that its vaccine Shingrix has been approved in Canada for the prevention of shingles (herpes zoster) in people aged between 50 years or more.
Bayer to Sell Select Business Lines to Close Monsanto Buyout
by Zacks Equity Research
Bayer Aktiengesellschaft (BAYRY) inked a deal to sell selected Crop Science businesses to BASF for EUR 5.9 billion to as a part of its strategy to complete the planned acquisition of Monsanto Co.
J&J's Psoriasis Drug Stelara Gets FDA Nod for Adolescent Use
by Zacks Equity Research
Johnson & Johnson (JNJ) announced approval of label expansion for its plaque psoriasis drug, Stelara, to include adolescent patients.
Valeant Reports Positive Results on Psoriasis Drug Siliq
by Zacks Equity Research
Valeant Pharmaceuticals International, Inc. (VRX) announced encouraging results from the long-term phase III extension study, AMAGINE-2 on psoriasis drug Siliq.
Here's Why Intercept (ICPT) Stock Lost 37% So Far in 2017
by Zacks Equity Research
Shares of Intercept Pharmaceuticals (ICPT) have plunged 37% in the year so far due to safety issues regarding approved drug Ocaliva.
Biotech Stock Roundup: Amgen's Imlygic Data Promising, Regeneron Scores Win in PCSK9 Lawsuit
by Arpita Dutt
With third quarter earnings round the corner, it was a relatively slow week with key updates including Regeneron (REGN) and partner Sanofi's win in the PCSK9 litigation.
Mallinckrodt to Begin Sarcoidosis Study on Acthar Gel
by Zacks Equity Research
Mallinckrodt plc (MNK) announced that it will initiate a new phase IV study on H.P. Acthar Gel as a therapy option in patients with symptomatic sarcoidosis.
Amgen Label Expansion Application for Prolia Accepted by FDA
by Zacks Equity Research
Amgen (AMGN) announced that the FDA has accepted its regulatory application in the U.S. seeking label expansion for Prolia for treating patients with glucocorticoid-induced osteoporosis (GIOP).
Forget Teva (TEVA), Buy These 5 Drug Stocks Instead
by Arpita Dutt
With another challenge cropping up for Teva (TEVA) in the form of earlier-than-expected generic competition for the 40 mg dose of Copaxone, here is a look at 5 drug stocks that look better-positioned.
Amgen Enters Into an Immuno-Oncology Partnership With CytomX
by Zacks Equity Research
Amgen (AMGN) has entered into a strategic immuno-oncology collaboration with CytomX to jointly develop a T-cell engaging bispecific probody.
3 Top-Ranked Big Biotech Stocks to Buy Now
by Zacks Equity Research
With biotech stocks on a tear, here we have picked three of the biggest biotech companies which look well poised for growth and can be added to one's portfolio
Here's Why Bluebird Bio (BLUE) Stock Is Falling Today
by Ryan McQueeney
Shares of Bluebird Bio (BLUE), a major player in the emerging gene therapy and CAR-T research markets, slumped more than 6% in morning trading Monday after receiving a key analyst downgrade.
Roche (RHHBY) Gets Approval for Label Expansion of Tecentriq
by Zacks Equity Research
Roche Holding AG (RHHBY) announced a label expansion of immunotherapy drug Tecentriq for the treatment of non-small cell lung cancer in Europe.
Juno Tenders $250M Follow-on Public Offering of Common Stock
by Zacks Equity Research
Juno Therapeutics (JUNO) launches a proposed follow-on public offering of shares. The company plans to utilize net proceeds from the offering for general corporate purposes.
Top Research Reports for Northrop Grumman, BNY Mellon & Celgene
by Zacks Equity Research
Today's Research Daily features new research reports on 16 major stocks, including Northrop Grumman (NOC), Bank of New York Mellon (BK) and Celgene (CELG)
Roche (RHHBY) Announces Positive Data on Leukemia Drug
by Zacks Equity Research
Roche Holdings AG (RHHBY) announced positive results from the phase III study, MURANO on leukemia drug Venclexta.
Roche's (RHHBY) Tecentriq Studies Put on Partial Hold by FDA
by Zacks Equity Research
Roche Holdings AG (RHHBY) announced that the FDA has put a partial clinical hold on a phase Ib and phase I/II b trials evaluating immunotherapy drug Tecentriq.
Celgene (CELG) Fusion Program Studies Put on Hold by FDA
by Zacks Equity Research
Celgene Corporation (CELG) announced that the FDA put a hold on several trials in the FUSION program evaluating Imfinzi, an anti-PD-L1 antibody, in combination with immunomodulatory and chemotherapy agents in blood cancers.